Natalizumab is an antibody against cell adhesion molecule α4-integrin that is clinically approved for the treatment of multiple sclerosis [98], and has been shown to activate Nrf2 and decrease markers of oxidative stress in peripheral blood mononuclear cells of multiple sclerosis patients [242], suggesting Nrf2 activation may be involved in its therapeutic action (Table 2). The gene discussed is NFE2L2; the disease is multiple sclerosis.